Triptorelin Market Size

Triptorelin Market size was over USD 11.1 billion in 2024 and is poised to exceed USD 21.99 billion by 2037, witnessing over 5.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of triptorelin is evaluated at USD 12.08 billion.

The growing prevalence of central precocious puberty among children below the age of 8 or 9 is poised to dominate the market demand for triptorelin. Moreover, its frequency has been boosted since covid19 owing to growing stress among children. Hence, the use of triptorelin increased and is anticipated to boost even further owing to this factor. Triptorelin injection (Triptodur) for the treatment of central precocious puberty (CPP), a condition that causes puberty in children at an early stage and leads to faster bone growth and sexual traits development, in children aged 2 and older.

Inconsistency between biological sex and self-identified gender is a problem for transgender people. Hence, the use of triptorelin is also growing among transgender people for hormone replacement therapy. Hormone therapy is a common transitional treatment for transgender men and women. To promote virilization and decrease feminizing traits in transgender men, exogenous testosterone is administered. Anti-androgens are used as adjuncts to help suppress masculinizing characteristics in transgender women, and exogenous estrogen is used to help feminize patients. Moreover, triptorelin has the function of enabling control over ovarian function during ovarian stimulation cycles. It suppresses the LH peak that triggers ovulation, preventing spontaneous ovulation as a result. Additionally, it permits tracking of ovarian activity in people who have frozen embryo transfers or egg donation cycles and have an ovarian function. As a result, the endometrium could be in the best possible shape for embryo implantation.